Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. is listed today as Amylyx Pharmaceuticals, Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2020 | $30 M | No. 3 | $10 to $50 million | equity | SEC | |
| Aug 2016 | $4 M | No. 2 | $2 to $10 million | equity | SEC | |
| Mar 2014 | $1 M | No. 1 | Under $2 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Amylyx Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2020).
SEC Form D · Jul 2020
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jul 2020
That is all the official record says: Amylyx Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Amylyx Pharmaceuticals, Inc. are on record.
Investors#
11 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| ALS Invest 1 B.V. | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| George M. Milne Jr. | Person | not stated | not stated | Held Series A, B, C-1 and C-2 preferred stock, director (Form 3, 2022) | SEC Form 3 |
| Joshua B. Cohen | Person | not stated | not stated | Held Series C-1 preferred stock, director (Form 3, 2022) | SEC Form 3 |
| Justin B. Klee | Person | not stated | not stated | Held Series C-1 preferred stock, director (Form 3, 2022) | SEC Form 3 |
| Morningside Venture Investments Ltd | Venture capital | not stated | not stated | Held Series A, B, C-1 and C-2 preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Mvil, LLC | Other | not stated | not stated | Held Series A, B, C-1 and C-2 preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Viking Global Investors LP | Fund or asset manager | not stated | not stated | Held Series C-1 preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Viking Global Opportunities GP LLC | Other | not stated | not stated | Held Series C-1 preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Viking Global Opportunities Illiquid Investments Sub-Master LP | Fund or asset manager | not stated | not stated | Held Series C-1 preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Viking Global Opportunities Parent GP LLC | Other | not stated | not stated | Held Series C-1 preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Viking Global Opportunities Portfolio GP LLC | Other | not stated | not stated | Held Series C-1 preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 28 investors.
Largest shareholders today
Institutions holding Amylyx Pharmaceuticals, Inc. shares, as of Sep 30, 2026.
- FMR LLC$580 M15.51%
- Perceptive Advisors LLC$308 M8.22%
- BlackRock, Inc.$302 M8.06%
- TCG Crossover Management, LLC$182 M4.86%
- Driehaus Capital Management LLC$158 M4.22%
- Janus Henderson Group Ltd.$157 M4.20%
- Vanguard Capital Management LLC$148 M3.95%
- Saturn V Capital Management LP$130 M3.48%
- Ra Capital Management, L.P.$125 M3.33%
- First Light Asset Management, LLC$116 M3.10%
- Franklin Templeton Inc$114 M3.06%
- Goldman Sachs Group Inc$104 M2.79%
- Jpmorgan Chase & Co$100 M2.67%
- Price T Rowe Associates Inc /MD/$91 M2.42%
- Morgan Stanley$81 M2.17%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Joshua Cohen | Executive officer | Jul 2020 |
| Justin Klee | Executive officer | Jul 2020 |
| Peter Finn | Executive officer | Jul 2020 |
| Peter B. Finn | Secretary | Nov 2015 |
| Felix Von Coerper | Director | Jul 2020 |
| George Milne | Director | Jul 2020 |
| Isaac Cheng | Director | Jul 2020 |
| Joshua Cohen | Director | Jul 2020 |
| Justin Klee | Director | Jul 2020 |
| Stephen Chubb | Director | Jul 2020 |
| Walter Gilbert | Director | Jul 2020 |
| George M. Milne, PH.D. | Director | Nov 2015 |
| Stephen D. Chubb | Director | Nov 2015 |
Went public since 2022. Its SEC number is that of a company listed on a stock exchange.